Prana Biotechnology PE Ratio 2010-2022 | ATHE

Current and historical p/e ratio for Prana Biotechnology (ATHE) from 2010 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Prana Biotechnology PE ratio as of February 03, 2023 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Prana Biotechnology PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2023-02-03 3.95 inf
2022-06-30 6.11 0 0.00
2021-12-31 7.20 0 0.00
2021-06-30 13.00 0 0.00
2020-12-31 13.40 0 0.00
2020-06-30 11.90 0 0.00
2019-12-31 7.80 0 0.00
2019-06-30 13.10 0 0.00
2018-12-31 12.80 0 0.00
2018-06-30 18.89 0 0.00
2017-12-31 31.20 0 0.00
2017-06-30 22.90 0 0.00
2016-06-30 47.42 0 0.00
2015-12-31 43.44 0 0.00
2015-06-30 70.20 0 0.00
2014-12-31 98.40 0 0.00
2014-06-30 135.90 0 0.00
2013-12-31 420.60 0 0.00
2013-06-30 139.20 0 0.00
2012-12-31 132.00 0 0.00
2012-06-30 94.20 0 0.00
2011-12-31 88.20 0 0.00
2011-06-30 114.60 0 0.00
2010-12-31 75.00 0 0.00
2010-06-30 67.20 0 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.016B $0.003B
Prana Biotechnology was established to commercialize research into Alzheimer's disease and other major age-related degenerative disorders. Their mission is to develop diagnostic and therapeutic drugs to treat the central disease pathways that cause degeneration of the brain as the aging process progresses. Prana's technology has emerged from its researchers at prominent international institutions such as Massachusetts General Hospital at Harvard Medical School and the University of Melbourne.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00